drugset / Trial / NCT02624999

Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck

NCT02624999

Phase 2 Withdrawn Mirror Biologics, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase II, Randomized, Non-Inferiority Study Comparing an Individualized Cancer Vaccine (AlloVax™) to Chemotherapy in Subjects with R/M SCCHN .

Timeline

Start
2016-12
Primary completion
2016-12
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AlloVax Vaccine
Comparator Cisplatin Other / unclassified 80 mg/m2 Intravenous
Comparator Cisplatin Other / unclassified 100 mg/m2 Intravenous
Comparator fluorouracil Small molecule 1000 mg/m2 Intravenous